1. At a Glance – Blink and You’ll Miss the Drama
Jubilant Pharmova is trading at ₹938, down ~17% in the last 3 months, with a ₹14,937 Cr market cap and a Stock P/E of 32.4 — which already smells rich for a company whose ROE is stuck at ~9.5% like a Delhi car in August traffic.
Q3 FY26 numbers just dropped and they’re… spicy.
Revenue came in at ₹2,123 Cr (+17% YoY), but reported PAT fell ~31% YoY to ₹56 Cr, thanks to FDA hangovers, CDMO shutdown costs, depreciation bombs, and interest doing bhangra.
Debt stands at ₹2,883 Cr, but management swears reduction is coming — mainly funded by selling their Sofie Biosciences stake for ~$139 Mn.
Radiopharma alone contributes ~44% of revenue, and if Radiopharma sneezes, Jubilant catches pneumonia.
This is not a “steady compounder” story.
This is a “one FDA letter away from chaos, one approval away from glory” story.
Curious already? Good. Because it only gets messier.
2. Introduction – This Is Not One Business, It’s Six Wearing One Share Price
Jubilant Pharmova is what happens when a conglomerate refuses to pick a lane.
They do:
- Nuclear medicine
- Allergy shots
- Sterile injectables
- US generics
- Drug discovery services
- Experimental oncology molecules
Most pharma companies choose one poison. Jubilant said: “Why not drink all of them?”
The result?
A company with world-class assets, global reach, FDA scars, lumpy earnings, and a valuation that assumes things will eventually go right.
Historically, Jubilant has suffered from:
- Over-expansion
- Regulatory whiplash
- Capital misallocation
- ROE that looks like it skipped leg day
But lately, there’s been an attempt at adult supervision:
- Non-core exits
- Debt reduction
- Capacity consolidation
- Focus on Radiopharma + CDMO
Is it working?
Partially. But the market wants proof, not PowerPoint.
3. Business Model – WTF Do They Even Do?
Let’s break this monster down, one organ at a time.
a) Radiopharmaceuticals (~44% of 9MFY24
